20-Mar-2025 4:12 AM CST - Yahoo Finance Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks Let's dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
18-Mar-2025 6:35 AM CST - Yahoo Finance Health Canada approves Biogen's Skyclarys for Friedreich's ataxia Health Canada has granted approval for Biogen's Skyclarys (omaveloxolone) to treat Friedreich's ataxia (FA), a rare, progressive neurodegenerative disease, in individuals aged 16 years and above. The approval,
6-Mar-2025 12:56 AM CST - Business Insider Biogen (BIIB) Receives a Hold from Bernstein In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB - Research Report), with a price
4-Mar-2025 11:01 AM CST - Benzinga 4BIIB : What the Options Market Tells Us About Biogen High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
28-Feb-2025 9:07 AM CST - Morningstar Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.
28-Feb-2025 7:31 AM CST - Business Insider Biogen, Eisai confirm CHMP positive opinion for lecanemab Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has
20-Feb-2025 7:15 AM CST - MSN Biogen Stock Is Mutating Into a Value Play Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.
18-Feb-2025 11:35 AM CST - MSN Biogen Bets Up to $550 Million for Rights to Epilepsy Drug Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.
20-Mar-2025 4:12 AM CST - Yahoo Finance Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks Let's dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
18-Mar-2025 6:35 AM CST - Yahoo Finance Health Canada approves Biogen's Skyclarys for Friedreich's ataxia Health Canada has granted approval for Biogen's Skyclarys (omaveloxolone) to treat Friedreich's ataxia (FA), a rare, progressive neurodegenerative disease, in individuals aged 16 years and above. The approval,
6-Mar-2025 12:56 AM CST - Business Insider Biogen (BIIB) Receives a Hold from Bernstein In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB - Research Report), with a price
4-Mar-2025 11:01 AM CST - Benzinga 4BIIB : What the Options Market Tells Us About Biogen High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
28-Feb-2025 9:07 AM CST - Morningstar Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.
28-Feb-2025 7:31 AM CST - Business Insider Biogen, Eisai confirm CHMP positive opinion for lecanemab Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has
20-Feb-2025 7:15 AM CST - MSN Biogen Stock Is Mutating Into a Value Play Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.
18-Feb-2025 11:35 AM CST - MSN Biogen Bets Up to $550 Million for Rights to Epilepsy Drug Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.
